Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Importin-13 (IPO13) is a unique member of the importin-β/Karyopherin superfamily that functions as a nuclear transport receptor, mediating both the import and export of a variety of cargo proteins across the nuclear envelope in a Ran-dependent (and sometimes Ran-independent) manner. IPO13 directs the nucleocytoplasmic trafficking of key regulatory proteins—including transcription factors like glucocorticoid receptor, SP1, KLF4, homeodomain proteins Pax6, ARX, UBC9, and others—integral to anti-inflammatory signaling, stress response, gene expression, and cell fate decisions. Unlike most importins, IPO13 is active even under cellular stress, controlling nuclear import (e.g., of nCLU, which promotes apoptosis) and regulating export (e.g., KU70, involved in DNA repair). IPO13 thereby influences the response to oxidative stress, cell cycle progression, and apoptosis, and its altered function or genetic mutations can contribute to developmental abnormalities and disease. Phosphorylation of IPO13 further modulates its subcellular localization and transport activity, with implications for distribution of transcription partners such as Pax6 in development[1][2][3][4][5].
Not applicable/none known for drugs, but as a transporter, IPO13 mediates nuclear import of proteins such as UBC9, Pax6, Pax3, CRX, ARX, glucocorticoid receptor, and nuclear export of eIF1A, EIF4G2, HMG20A, KLF4, and SP1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Importin-13 (IPO13).